Market research
MLTX MoonLake Immunotherapeutics
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 28.5385
- Dividend yield
- Not available
- Beta
- 1.03
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- KY61559X1045
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 28.5385
- Dividend yield
- Not available
- Beta
- 1.03
About
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the MLTX discussion.
No comments yet
Start a focused discussion about MLTX.